Allovir Ownership
| ALVR Stock | USD 0.45 0.01 2.17% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 115.1 M | Current Value 115.4 M | Avarage Shares Outstanding 73.6 M | Quarterly Volatility 27.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Allovir |
Allovir Stock Ownership Analysis
About 49.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allovir recorded a loss per share of 0.9. The entity had not issued any dividends in recent years. The firm had 1:10 split on the April 2, 2013. Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people. For more info on Allovir please contact Diana MD at 617 433 2605 or go to https://www.allovir.com.Besides selling stocks to institutional investors, Allovir also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Allovir's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Allovir's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Allovir Quarterly Liabilities And Stockholders Equity |
|
About 49.0% of Allovir are currently held by insiders. Unlike Allovir's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Allovir's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Allovir's insider trades
Allovir Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Allovir is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allovir backward and forwards among themselves. Allovir's institutional investor refers to the entity that pools money to purchase Allovir's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rbf Llc | 2024-09-30 | 449 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 324.7 K | Fmr Inc | 2024-09-30 | 310.6 K | D. E. Shaw & Co Lp | 2024-09-30 | 296.5 K | Two Sigma Investments Llc | 2024-09-30 | 295.2 K | State Street Corp | 2024-09-30 | 222.4 K | Commonwealth Equity Services Inc | 2024-09-30 | 201 K | Marquette Asset Management Inc. | 2024-09-30 | 178.9 K | Jane Street Group Llc | 2024-06-30 | 173 K | Ecor1 Capital, Llc | 2024-09-30 | 11.3 M | Octagon Capital Advisors Lp | 2024-09-30 | 11.2 M |
Allovir Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allovir insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allovir's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allovir insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Allovir Outstanding Bonds
Allovir issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Allovir uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Allovir bonds can be classified according to their maturity, which is the date when Allovir has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Pair Trading with Allovir
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.Moving together with Allovir Stock
Moving against Allovir Stock
| 0.78 | DYAI | Dyadic International | PairCorr |
| 0.67 | ESPR | Esperion Therapeutics | PairCorr |
| 0.63 | BMY | Bristol Myers Squibb | PairCorr |
| 0.45 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
| 0.36 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.